New Arizona PIRG-backed legislation signed by the president in September should make the drugs we put in our medicine cabinets a little safer.
Arizona PIRG urged our state’s congressional delegation to stand behind provisions that would require greater transparency in clinical trials of new drugs, greater independence on FDA drug safety pan-els and greater accountability for drug companies that fail to perform required safety studies—including fines of up to $10 million.
According to Paul Brown, our lead advocate on the issue, controversies surrounding the harmful side effects of drugs such as Vioxx, Paxil and Avandia left members of Congress more open to our push for reform. “In the end,” Brown said, “there were too many headlines about dangerous drugs. Congress had to act and we are pleased they did.”
The bill’s near-unanimous final approval belied the intense debate that surrounded its key provisions. Arizona PIRG made it a priority to require drug companies to disclose clinical trial results—a step vehemently opposed by drug industry lobbyists.